A Clinical Guide to Polyendocrine Metabolic Ovarian Syndrome

Author: Min Geraets | BNatMed | Naturopath & Medical Herbalist

Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly known as Polycystic Ovary Syndrome (PCOS), is the most common endocrine disorder affecting women of reproductive age. It is estimated to affect 1 in 8 reproductive-aged women globally and often up to 70% of affected individuals remain undiagnosed due to inconsistencies in the diagnostic criteria.¹ Undiagnosed women often experience symptoms for years before receiving appropriate investigation and management.

The syndrome has traditionally been viewed through a reproductive lens, with clinical attention focused on irregular menstruation, infertility and polycystic ovarian morphology. Since 2000 however, research has fundamentally changed our understanding of the condition. PMOS is no recognised as a complex, lifelong endocrine-metabolic disorder involving disturbances in insulin signalling, androgen production, hypothalamic-pituitary ovarian (HPO) axis regulation, adipose tissue biology, chronic inflammation and cardiovascular risk. Reproductive dysfunction represents only one manifestation of a multisystem condition that affects metabolic, psychological and long-term health outcomes.²

Reflecting this broader understanding, an international multidisciplinary consensus process in 2026 recommended renaming PCOS to PMOS. Its argument was that the previous name placed undue emphasis on ovarian morphology, despite many affected individuals not having polycystic ovaries and many with polycystic ovarian morphology not having the syndrome. The recommendation was adopted, with the new terminology acknowledging PMOS as a complex multisystem disorder involving endocrine dysregulation, metabolic dysfunction, reproductive disturbance, and chronic inflammation.

This shift reinforces what practitioners have long recognised-that successful PMOS management requires addressing the interconnected physiological drivers of the condition rather than focusing solely on menstrual irregularity or fertility.

Why PMOS matters beyond reproductive health

Although PMOS is commonly diagnosed following menstrual irregularity or difficulty conceiving, its clinical significance extends far beyond fertility. Longitudinal studies consistently demonstrate that individuals with PMOS have substantially increased risks of:

Insulin resistance and hyperinsulinaemia
Impaired glucose tolerance
Type 2 diabetes mellitus
Metabolic syndrome
Dyslipidaemia
Hypertension
Non-alcoholic fatty liver disease (NAFLD)
Obstructive sleep apnoea
Cardiovascular disease
Pregnancy complications
Endometrial hyperplasia and carcinoma
Anxiety and depressive disorders.^2-3

The role of the practitioner

PMOS presents particularly well to integrative healthcare, because many of its underlying mechanisms are amenable to lifestyle modification and nutritional intervention. Rather than focusing exclusively on symptom suppression, naturopathic and herbal approaches seek to improve the physiological processes driving disease progression, including:

Impaired insulin sensitivity
Chronic low-grade inflammation
Oxidative stress
Altered hypothalamic-pituitary signalling
Adipose tissue dysfunction
Nutritional insufficiency
Gastrointestinal dysbiosis
Psychological stress.

This systems-based framework complements conventional medical management and provides opportunities to improve both symptom burden and long-term cardiometabolic outcomes.

A changing clinical paradigm

Historically, treatment often centered on regulating menstruation using combined oral contraceptives or inducing ovulation when fertility was desired. While these interventions remain appropriate in some situations, they do not address the underlying metabolic abnormalities driving disease progression.

Current international guidelines emphasise a broader therapeutic framework focused on:

Improving insulin sensitivity
Reducing cardiometabolic risk
Supporting healthy body composition
Restoring ovulatory function where appropriate
Reducing hyperandrogenic symptoms
Improving mental health and quality of life
Preventing long-term complications.³

Understanding the pathophysiology

PMOS develops through interactions between genetic susceptibility, epigenetic influences, environmental factors, endocrine dysfunction and metabolic disturbances.⁴ Rather than a single disease process, it represents multiple overlapping phenotypes.

Although clinical presentation varies considerably between individuals, these physiological disturbances are highly interconnected. They form a series of self-reinforcing feedback loops that contribute to the persistence and progression of the syndrome throughout one's lifetime.

For clinicians, understanding these mechanisms is fundamental. It explains why interventions that improve insulin sensitivity often result in improvements across seemingly unrelated symptoms such as acne, menstrual irregularity, infertility and metabolic dysfunction.

Insulin resistance: The metabolic engine of PMOS

Among all recognised pathological mechanisms, insulin resistance is considered one of the principal drivers of PMOS. Approximately 75-85% of individuals with PMOS exhibit measurable insulin resistance, although prevalence varies according to phenotype, ethnicity and body composition.¹ Importantly, insulin resistance is not exclusive to obesity, highlighting that impaired insulin signalling is intrinsic to the syndrome rather than a sole consequence of excess adiposity.⁵

Insulin resistance develops when skeletal muscle, liver and adipose tissue becomes less responsive to circulating insulin. To maintain normal blood glucose concentrations, pancreatic β-cells compensate by secreting progressively larger amounts of insulin, resulting in hyperinsulinaemia.⁶

Hyperinsulinaemia and ovarian steroidogenesis

The ovaries remain highly responsive to insulin, even when peripheral tissues have become insulin resistant. Within ovarian theca cells, insulin acts synergistically with luteinising hormone (LH) to stimulate androgen production.⁴ This occurs primarily through increased activity of steroidogenic enzymes including CYP17A1, leading to greater synthesis of testosterone.⁷

At the same time, insulin suppresses hepatic synthesis of SHBG (sex-hormone binding globulin), increasing the proportion of biologically active free testosterone in circulation. Elevated androgen concentrations interfere with normal follicular maturation. Rather than progressing to ovulation, multiple follicles arrest during early development, producing the characteristic appearance of numerous small antral follicles on ultrasound.⁷

Importantly, these structures are not ovarian cysts. They are immature follicles that have failed to complete normal development. This distinction was one of the key reasons underpinning the decision to replace the term 'polycystic ovary syndrome' with PMOS.¹

Hyperandrogenism

Hyperandrogenism is one of the defining features of PMOS and contributes to both reproductive and metabolic dysfunction.

Clinical manifestation include:

Hirsutism (excessive hair growth)
Acne
Androgenic alopecia
Menstrual irregularity
Weight gain.¹

Androgens promote preferential accumulation of visceral adipose tissue, which in turn secretes greater concentrations of pro-inflammatory cytokines and adipokines.⁷ This contributes to worsening insulin resistance, creating a self-perpetuating metabolic cycle.

Interestingly, not all individuals with PMOS demonstrate elevated serum testosterone concentrations despite clear clinical features of androgen excess. Measurement of free androgen index or calculated free testosterone is often more clinically informative than total testosterone alone.³

Neuroendocrine dysregulation

PMOS also involves disturbances within the HPO axis. Under normal physiological conditions, gonadotrophin-releasing hormone (GnRH) is released from the hypothalamus in rhythmic pulses that regulate secretion of LH and follicle-stimulating hormone (FSH) from the anterior pituitary.⁹

In PMOS, increased GnRH pulse frequency favours LH secretion over FSH production.⁹ This altered hormonal pattern contributes to:

Excessive ovarian androgen synthesis
Impaired follicle maturation
Oligo- or anovulation
Menstrual irregularity.⁹

Emerging evidence suggests that hyperandrogenism itself may alter hypothalamic sensitivity to steroid hormone feedback, reinforcing abnormal GnRH pulsatility and perpetuating the disorder.⁷

The neuroendocrine component highlights why chronic stress, disrupted sleep and circadian dysregulation often exacerbate symptoms.

Chronic low-grade inflammation and oxidative stress

A growing body of evidence supports the concept that PMOS represents a state of chronic low-grade inflammation.⁴ Compared with healthy controls, affected individuals commonly demonstrate increased circulating concentrations of:

C-reactive protein (CRP)
Tumour necrosis factor-α (TNF-α)
IL-6.

These inflammatory mediators interfere with insulin receptor signalling and contribute to oxidative stress, endothelial dysfunction and cardiovascular disease.¹⁰

Reactive oxidative species (ROS) are increasingly recognised as important mediators of PMOS-associated metabolic dysfunction. Oxidative stress damages cellular proteins, lipids and DNA, while impairing insulin signalling pathways. Studies have demonstrated reduced antioxidant capacity and increased lipid peroxidation in women with PMOS, findings that correlate with worsening insulin resistance and infertility.¹¹

Importantly, inflammation appears to persist even after adjustment for body mass index in several studies, suggesting that it is an intrinsic feature of the syndrome rather than simply a consequence of obesity.¹² This provides a strong rationale for dietary and herbal interventions with demonstrated anti-inflammatory activity.

Adipose tissue as an endocrine organ

Adipose tissue is increasingly recognised as an active endocrine organ rather than a passive energy store.

Visceral adipose tissue secretes numerous biologically active molecules, including:

Leptin
Adiponectin
Resistin
TNF-α
IL-6.¹³

In PMOS, excess visceral adiposity is associated with reduced adiponectin concentrations, impaired insulin sensitivity and increased secretion of pro-inflammatory cytokines.¹³

It is important to note that PMOS also effects lean individuals, emphasising that adiposity is a contributor rather than the primary cause.

Genetics and epigenetics

PMOS demonstrates strong familial clustering, with heritability estimates approaching 70% in some populations.⁴

Genome-wide associations studies have identified multiple genes and proteins involved in:

Insulin signalling
Sex hormone function
Regulation of metabolism.⁴

However, no single genetic mutation explains the syndrome. Instead, PMOS is considered a polygenic disorder in which numerous genetic variants interact with environmental influences such as nutrition, endocrine-disrupting chemicals, stress and physical inactivity.⁴

Epigenetic mechanisms such as DNA-methylation can help explain why clinical presentations varies substantially among individuals with similar genetic backgrounds.⁴ These findings also support the growing emphasis on lifestyle interventions capable of modifying gene expression through improvements in metabolic health.

The gut microbiome

Emerging research suggests alterations in gut microbial diversity may influence:

Insulin sensitivity
Obesity
Systemic inflammation
Androgen metabolism
Bile acid metabolism
Embryo development
Pregnancy outcomes.¹⁴

Although casual relationships remain under investigation, proposed mechanisms include increased intestinal permeability, endotoxin-mediated inflammation and altered short-chain fatty acid production.¹⁴

Dietary fibre, polyphenol-rich foods and fermented foods positively influence microbial diversity, while selected probiotic strains have shown modest improvements in insulin sensitivity and inflammatory markers in early clinical trials.

An integrated model of PMOS

Rather than viewing the various pathophysiological mechanisms as separate processes, it is more accurate to conceptualise PMOS as a network of interconnected physiological disturbances.

Hyperinsulinaemia drives ovarian androgen production
Excess androgens worsen insulin resistance
Visceral adiposity amplifies inflammatory cytokine production
Inflammation impairs insulin signalling
Oxidative stress damage's ovarian function
Neuroendocrine dysregulation perpetuates anovulation.

Each process reinforces the next, creating multiple self-sustaining feedback loops.

Clinical presentation

PMOS presents differently across the lifespan. Symptoms typically emerge during adolescence and may evolve through reproductive years and menopause.

Reproductive features

Irregular menstrual cycles
Oligo- or amenorrhoea
Anovulation
Infertility
Recurrent miscarriage
Pregnancy complications.³

Hyperandrogenic features

Facial and body hirsutism
Acne
Androgenic alopecia.³

Metabolic features

Central weight gain
Difficulty losing weight
Insulin resistance.³

Psychological features

Mental health symptoms are highly prevalent yet frequently overlooked. These include:

Anxiety
Depression
Eating disorders
Reduced self-esteem
Body image concerns
Impaired quality of life.³

Routine psychological screening should be incorporated into clinical assessment, alongside appropriate referral where necessary.

Diagnostic criteria

Despite the adoption of the term PMOS, the internationally accepted diagnostic criteria remain unchanged. The modified Rotterdam criteria continue to be recommended following exclusion of alternative endocrine disorders.²

Diagnosis requires the presence of two of the following three features:

Oligo- or anovulation.²
Clinical and/or biochemical hyperandrogenism.²
Polycystic ovarian morphology on ultrasound, or elevated anti-Müllerian hormone (AMH) where appropriate and validated.²

Importantly, ultrasound is not recommended for routine diagnosis in adolescents because multifollicular ovaries are common during normal pubertal development.

Differential diagnosis

Several endocrine disorders may mimic PMOS and should be excluded before diagnosis. These include:

Thyroid dysfunction
Hyperprolactinaemia
Non-classical congenital adrenal hyperplasia
Cushing syndrome
Androgen-secreting ovarian or adrenal tumours
Hypothalamic amenorrhoea
Acromegaly
Primary ovarian insufficiency.¹⁵

Careful case-taking and targeted laboratory investigations are essential for accurate diagnosis.

Laboratory assessment

Baseline pathology should extend beyond reproductive hormones to include comprehensive metabolic assessment.

Endocrine investigations

Recommend investigations include:

Total testosterone
Calculated free testosterone or free androgen index
SHBG
Dehydroepiandrosterone sulfate (DHEA-S)
Androstenedione (where indicated)
LH/FSH
Oestradiol + FSH
17-OH progesterone
Prolactin
Thyroid-stimulating hormone (TSH)
AMH (where clinically appropriate).¹⁶

Hormonal testing should ideally be performed during the early follicular (day 2-4) phase in menstruating clients.¹⁶

Metabolic investigations

Comprehensive metabolic assessment should include:

Fasting glucose
HbA1c
Oral glucose tolerance test
Fasting lipid profile
Liver function tests
Renal function
Blood pressure
Waist circumference.^3,17

The oral glucose tolerance test remains the most sensitive method for identifying impaired glucose tolerance and is recommended for clients at increased risk of diabetes, including those planning pregnancy.³

Clinical assessment beyond pathology

Perhaps the most valuable information is obtained during a comprehensive consultation. Areas warranting careful exploration include:

Menstrual history
Reproductive goals
Dietary habits
Physical activity
Sleep quality
Stress exposure
Family history of diabetes or cardiovascular disease
Medication history
Body image and eating behaviours
Psychological wellbeing.

Therapeutic approaches

Lifestyle intervention remains the first line and most evidence-based component of PMOS management. Even modest improvements in diet, physical activity and sleep quality can significantly improve insulin sensitivity, ovulatory function and metabolic outcomes.³

1. Dietary strategies

Dietary intervention in PMOS is best conceptualised as a metabolic rather than restrictive approach. This reduces psychological distress and improves adherence while still producing clinically meaningful outcomes.

The strongest evidence supports dietary patterns that improve insulin sensitivity and reduce systemic inflammation, particularly:

Mediterranean-style dietary patterns
Low glycaemic load diets.

These approaches improve postprandial glucose regulation, reduce insulin demand, lower inflammation and support gut microbiome diversity. Clinical trials demonstrate that reducing glycaemic load improves menstrual regularity, androgen levels and insulin sensitivity, even without caloric restriction.¹⁸

Key nutritional principles include:

Prioritising whole foods over ultra-processed foods
Ensuring adequate protein intake with each meal to support satiety and glucose regulation
Increasing dietary fibre to at least 25-30 g/day
Including omega-3-rich foods (e.g. oily fish, flaxseed, chia seeds, walnuts)
Balancing each meal with protein, fibre, healthy fats and complex carbohydrates to reduce total glycaemic load.

2. Lifestyle interventions

Lifestyle intervention remains the cornerstone of PMOS management. Even modest improvements in insulin sensitivity can substantially improve endocrine function.

Physical activity - Exercise improves insulin sensitivity via both insulin-dependent and insulin-independent pathways and is one of the most effective interventions for improving metabolic health in PMOS. Evidence supports a combination of resistance training (2 non-consecutive sessions per week), moderate-intensity aerobic exercise (150-300 minutes per week) and a reduction in sedentary behaviour. Resistance training is particularly important, as increased skeletal muscle mass improves glucose disposal and reduces insulin resistance. Aerobic exercise enhances cardiovascular fitness, reduces visceral adiposity and improves inflammatory markers.¹⁹ Importantly, exercise improves insulin sensitivity independent of weight loss.
Sleep and circadian rhythm - Sleep disturbance is common in PMOS and contributes to worsening insulin resistance, appetite dysregulation, increased cortisol activity and systemic inflammation.²⁰ Assessment should include sleep duration, quality and screening for obstructive sleep apnoea in high-risk individuals. Interventions may include, consistent sleep-wake timing, reduction of evening light exposure, management of sleep apnoea where applicable and stress reduction strategies.
Stress and the HPA axis - Chronic psychological stress influences hypothalamic-pituitary-adrenal (HPA) axis activity and may exacerbate neuroendocrine dysfunction in PMOS. Elevated cortisol is associated with increased visceral adiposity, impaired insulin sensitivity, menstrual irregularity and increased androgen production.²¹ Mind-body interventions such as mindfulness-based stress reduction, yoga, breathwork and counselling have demonstrated improvements in psychological outcomes and, in some cases, metabolic markers.

3. Herbal medicine

Herbal medicine offers a multi-targeted approach to PMOS by influencing insulin sensitivity, androgen metabolism, inflammation and neuroendocrine regulation.

Insulin-sensitising herbs

Berberine containing herbs, Barberry (Berberis vulgaris), Coptis (Coptis chinensis), Oregon grape (Mahonia aquifolium) - Berberine is one of the most extensively studied phytochemicals in metabolic disorders. It has demonstrated improvements in fasting insulin, insulin resistance (HOMA-IR), lipid profiles and ovulation rates in PMOS. Its mechanisms include activation of AMP-activated protein kinase (AMPK), modulation of gut microbiota and improved insulin receptor signalling.^22-23
Cinnamon (Cinnamomum verum) - Cinnamon has demonstrated modest clinical benefits in improving metabolic risk factors in women with PMOS. A 2021 systematic review evaluating the effects of Cinnamon supplementation in women with PMOS reported improvements in lipid profiles, including HDL cholesterol and significant reductions in LDL cholesterol and triglyceride levels. The review also found that Cinnamon enhanced glucose regulation by improving insulin sensitivity.²⁴ Supporting these findings, a 2018 clinical study reported that women with PMOS who received 500 mg of Cinnamomum verum capsules 3x/day for eight weeks experienced improvements in serum glucose levels and insulin sensitivity, along with a significant reduction in body weight.²⁵
Fenugreek (Trigonella foenum-graecum) - Traditionally used to support healthy blood glucose regulation and insulin sensitivity. Fenugreek may improve the metabolic features if PMOS by assisting glucose uptake into cells and reducing postprandial blood glucose spikes, while its cholesterol-lowering activity works to improve lipid profiles.²⁶
Gymnema (Gymnema slyvestre) - Traditionally used in Ayurvedic medicine for glycaemic control, Gymnema may reduce intestinal glucose absorption and improve pancreatic insulin secretion. A 2024 animal study showed Gymnema extract to decrease obesity, improve glucose metabolism, reduce inflammatory cytokines and improve liver enzyme values in PMOS mice.²⁷
Kawakawa (Macropiper excelsum) - Kawakawa has shown early clinical potential to improve insulin sensitivity, with a 2022 clinical study with healthy volunteers reporting enhanced postprandial insulin sensitivity and lower insulin concentrations following consumption of Kawakawa tea, suggesting more efficient glucose regulation.²⁸ Although the mechanisms remain under investigation and further studies in people with biochemical insulin-resistance are needed, these findings indicate Kawakawa may have therapeutic relevance for insulin-resistant conditions such as PMOS.
Kūmerahou (Pomaderris kumerahou) - Kūmerahou shows mechanistically plausible insulin-sensitising potential due to its flavonoids, saponins and polyphenols. These constituents have demonstrated the ability in preclinical studies to activate AMPK and AKT signalling, enhance GLUT-4 mediated glucose uptake, improve insulin signalling, suppress hepatic gluconeogenesis, and reduce inflammation and oxidative stress-pathways central to insulin resistance.²⁹ Although human clinical evidence is lacking, these actions suggest Kūmerahou may be relevant in conditions such as PMOS, where improving insulin sensitivity could help address a key underlying driver of metabolic and reproductive dysfunction.

Anti-androgenic herbs

Liquorice (Glycyrrhiza glabra) - Liquorice may benefit women with PMOS by reducing hyperandrogenism, which can improve symptoms such as hirsutism, acne, and ovulatory dysfunction. These effects are mechanistically plausible due to inhibition of androgen synthesis enzymes, including 17β-hydroxysteroid dehydrogenase and 17,20-lyase, while stimulating the effects of aromatase, reducing serum testosterone.³⁰
Paeony (Paeonia lactiflora) - Often used in combination with Liquorice, Paeony may help modulate androgen activity and support ovulatory function through its effects on ovarian steroidogenesis. It has been shown to positively influence low progesterone, reduce elevated androgens and help regulate oestrogen and prolactin.³¹
Spearmint (Mentha spicata) - Spearmint tea has shown reductions in free and total testosterone and improvements in hirsutism in small clinical studies.^32-33 It is a simple, low-risk adjunct particularly useful in mild hyperandrogenic presentations.

Anti-inflammatory and adjuvant herbs

Ginger (Zingiber officinale) - Ginger has been shown to improve glycaemic control and reduce inflammatory markers in PMOS.³⁴ In addition, a 2026 clinical trial found that supplementation with 2g/day Ginger for 12 weeks reduced total testosterone and free androgen index, increased serum SHBG concentrations and decreased the frequency of amenorrhoea and dysmenorrhoea in women with PMOS.³⁵
Green tea (Camellia sinensis) - Green tea extract has been clinically shown to significantly decrease body weight, BMI, waist circumference, body fat percentage and serum insulin in overweight or obese women with PMOS.³⁶
Nigella (Nigella sativa) - Nigella offers numerous potential benefits for the management of PMOS due to its anti-inflammatory, antioxidant, hypoglycaemic and hypolipidaemic effects, which are largely attributed to its active constituent, thymoquinone. Clinical studies have shown that Nigella extract can significantly improve fasting blood glucose, HOMA-IR, cholesterol and triglyceride levels. It has also been associated with improved menstrual regularity by reducing the interval between menstrual cycles and increasing the duration of menstruation.³⁷
Turmeric (Curcuma longa) - Turmeric's primary active constituent, curcumin, may help improve PMOS by reducing chronic inflammation and oxidative stress, enhancing insulin sensitivity, and improving glucose and cholesterol levels, while also lowering androgen levels that contribute to symptoms such as irregular periods and excess hair growth.³⁸

Supporting ovulation

Black cohosh (Cimicifuga racemosa) - Increase LH secretion is a hallmark feature of PMOS pathophysiology. Black cohosh works to limit LH secretion and the subsequent increase in androgens by reducing the release of GnRH. Black cohosh is associated with lower mid-cycle LH, higher serum oestradiol and progesterone in the second half, as well as thicker endometrium and shorter cycle length.³¹
Chaste-tree (Vitex agnus-castus) - Chaste-tree is known to help regulate HPO signalling. Animal studies have shown that it increases progesterone, oestrogen and FSH levels while reducing testosterone and LH levels.³⁹ These effects suggest it may help address the hormonal dysregulation associated with PMOS.

4. Nutritional supplementation

Nutritional supplements have been extensively studied in PMOS and represent one of the most evidence-based adjunctive therapies.

Myo-inositol (2000-4000 mg/day) - Myo-inositol is one of the most well-researched interventions in PMOS, demonstrating improvements in both metabolic and reproductive outcomes in meta-analyses. Clinical benefits include improved insulin sensitivity, restoration of ovulation, improved menstrual regularity and improved oocyte quality.⁴⁰ Myo-inositol shares clinical and hormonal benefits similar to metformin, without the mild gastrointestinal side effects.⁴¹
N-acetylcysteine (1200-1800 mg/day) - NAC is the precursor to the body's master endogenous antioxidant, glutathione. By reducing oxidative stress, an exacerbating factor in both insulin resistance and hyperandrogenaemia, NAC improves the ovarian microenvironment and promotes hormonal balance. These effects may enhance follicular development and ovulation, as reflected by the statistically significant increases in progesterone levels observed in clinical trials.⁴² NAC may be particularly beneficial for clients with oxidative stress-dominant presentations.
Omega-3 fatty acids (EPA/DHA 1000-2000 mg/day) - Omega-3 fatty acids demonstrate significant hypolipidaemic, cardioprotective and anti-inflammatory effects. Their anti-inflammatory properties provide a plausible mechanistic basis for their ability to modulate insulin resistance driven by chronic inflammation. Clinical studies have also shown that omega-3 fatty acid supplementation improves LH, testosterone, SHBG, CRP and total antioxidant capacity in women with PMOS.⁴³
Vitamin D (1000-4000 IU/day) - Vitamin D deficiency is highly prevalent in PMOS, estimated in about 67-87% of individuals. Correction of deficiency may improve insulin sensitivity, ovarian reserve, menstrual regularity, and inflammatory balance and decrease serum testosterone in PMOS.⁴⁴ Effects are more pronounced in deficient individuals.
Magnesium glycinate (300-400 mg) - Magnesium plays a role in glucose metabolism and insulin receptor function.⁴⁵ Supplementation may support insulin sensitivity, sleep quality and stress resilience.

Phenotype-based clinical reasoning

A useful clinical framework to identify the primary therapeutic entry point rather than attempting to address all pathways simultaneously at equal intensity.

1. Metabolic-dominant presentation

This group typically presents with:

Insulin resistance (biochemical or suspected)
Central adiposity or weight gain tendency
Fatigue and hunger shortly after meals
Dyslipidaemia
Family history of type 2 diabetes.

Primary clinical focus

The primary therapeutic objective is improving insulin sensitivity and glucose regulation. Clinical outcomes in this phenotype are strongly influenced by:

Dietary glycaemic modulation (ensuring adequate protein intake with each meal and focusing on low GI carbohydrates)
Skeletal muscle activation through resistance training
Insulin sensitising nutritional supplements
Herbal medicines with AMPK-modulating or glucose-regulating activity.

In this group, improvements in insulin sensitivity frequently result in secondary improvements such as:

Androgen levels
Ovulatory function
Acne severity
Menstrual regularity.

This reflects the hierarchical role of metabolic signalling in ovarian steroidogenesis.

2. Hyperandrogenic-dominant presentation

This phenotype is characterised by:

Acne (often inflammatory and persistent)
Hirsutism
Androgenic alopecia
Elevated serum androgens
Irregular cycles of variable severity.

Primary clinical focus

The therapeutic priority is modulation of androgen production and peripheral androgen activity. However, androgen excess rarely an isolated process. In most cases it is downstream of hyperinsulinaemia, meaning that metabolic interventions remain foundational even when cosmetic symptoms dominate the presentation.

Clinical data suggest combining the following strategies produces more consistent outcomes than targeting androgen pathways alone:

Insulin sensitisation
Anti-androgenic herbal support
Inflammatory modulation.

3. Ovulatory-dominant presentation

This phenotype typically presents with:

Infertility or subfertility
Oligo- or amenorrhoea
Anovulation (confirmed or suspected)
Mild metabolic or androgen symptoms.

Primary clinical focus

The key objective is restoration of ovulatory signalling through:

Improved insulin sensitivity
Regulation of HPO axis function
Reduction in oxidative stress burden
Support of follicular development.

In this group, even modest metabolic improvements can result in clinically meaningful; restoration of ovulation. Myo-inositol supplementation and lifestyle modification are often particularly relevant in this phenotype.

4. Inflammatory-dominant presentation

Some individuals present with a prominent inflammatory pattern, including:

Fatigue and low-grade systemic symptoms
Elevated CRP (where tested)
Insulin resistance disproportionate to body composition
Skin inflammation (acne).

Primary clinical focus

The therapeutic objective is reduction of systemic inflammatory load and oxidative stress. In this phenotype, herbal medicines and nutritional supplements with antioxidant and anti-inflammatory activity may have significant clinical impact.

Improvements in inflammatory status often enhances:

Insulin sensitivity
Ovarian function
Dermatological symptoms.

Key takeaways

PMOS is fundamentally an endocrine-metabolic syndrome rather than solely a reproductive disorder.
Hyperinsulinaemia often precedes abnormal fasting glucose by many years.
Lean individuals may have clinically significant insulin resistance.
Addressing insulin resistance frequently improves reproductive, dermatological and metabolic outcomes simultaneously.
Psychological wellbeing deserves equal attention alongside hormonal and metabolic management.
Early intervention reduces long-term cardiometabolic risk.
Sustainable lifestyle changes remain the foundation upon which herbal and nutritional therapies are built.
As research continues to advance, it is likely that PMOS will increasingly be understood as a preventable and modifiable condition when identified early and managed comprehensively.

References

1. Teede, H. J., Mahnaz Bahri Khomami, Morman, R., Laven, J. S. E., Joham, A. E., Costello, M. F., Patil, M., Rees, D. A., Berry, L., Cree, M. G., Zhao, H., Norman, R. J., Anuja Dokras, & Terhi Piltonen. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process. The Lancet, 470, 2329-2339. https://doi.org/10.1016/S0140-6736(26)00717-8

2. Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2(1). https://doi.org/10.1038/nrdp.2016.57

3. Teede, H., Chau Thien Tay, Laven, J., Anuja Dokras, Moran, L. J., Terhi Piltonen, Costello, M., Boivin, J., Redman, L. M., Boyle, J., Norman, R. J., Mousa, A., Joham, A. E., Arlt, W., Azziz, R., Balen, A., Bedson, L., Berry, L., Boivin, J., & Boyle, J. (2023). Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility, 120(4), 767–793. https://doi.org/10.1016/j.fertnstert.2023.07.025

4. Chan, J. L., Masini, I., & Pisarska, M. D. (2026). Polyendocrine metabolic ovarian syndrome (PMOS)/polycystic ovary syndrome (PCOS): Current and future trends. Journal of Clinical Investigation, 136(12). https://doi.org/10.1172/jci202824

5. Dunaif, A. (1997). Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocrine Reviews, 18(6), 774–800. https://doi.org/10.1210/edrv.18.6.0318

6. Accili, D., Deng, Z., & Liu, Q. (2025). Insulin resistance in type 2 diabetes mellitus. Nature Reviews Endocrinology, 10.1038/s41574-02501114-y. https://doi.org/10.1038/s41574-025-01114-y

7. Rosenfield, R. L., & Ehrmann, D. A. (2016). The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews, 37(5), 467–520. https://doi.org/10.1210/er.2015-1104

8. Ashraf, S., Nabi, M., Rasool, S. ul A., Rashid, F., & Amin, S. (2019). Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: A review. Egyptian Journal of Medical Human Genetics, 20(1). https://doi.org/10.1186/s43042-019-0031-4

9. Dong, J., & Rees, D. A. (2023). Polycystic ovary syndrome: Pathophysiology and therapeutic opportunities. BMJ Medicine, 2(1). https://doi.org/10.1136/bmjmed-2023-000548

10. Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270–284. https://doi.org/10.1038/nrendo.2018.24

11. Yan, H., Wang, L., Zhang, G., Li, N., Zhao, Y., Liu, J., Jiang, M., Du, X., Zeng, Q., Xiong, D., He, L., Zhou, Z., Luo, M., & Liu, W. (2024). Oxidative stress and energy metabolism abnormalities in polycystic ovary syndrome: From mechanisms to therapeutic strategies. Reproductive Biology and Endocrinology, 22(1). https://doi.org/10.1186/s12958-024-01337-0

12. Deng, H., Chen, Y., Xing, J., Zhang, N., & Xu, L. (2024). Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1470283

13. Bril, F., Ezeh, U., Amiri, M., Hatoum, S., Pace, L. E., Chen, Y., Bertrand, F. E., Gower, B. A., & Azziz, R. (2023). Adipose tissue dysfunction in polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism, 109(1), 10-24. https://doi.org/10.1210/clinem/dgad356

14. Qi, X., Yun, C., Pang, Y., & Qiao, J. (2021). The impact of the gut microbiota on the reproductive and metabolic endocrine system. Gut Microbes, 13(1), 1894070. https://doi.org/10.1080/19490976.2021.1894070

15. Williams, T., Mortada, R., & Porter, S. (2016). Diagnosis and treatment of polycystic ovary syndrome. American Family Physician, 94(2), 106-113. https://www.aafp.org/afp/2016/0715/p106

16. Dason, E. S., Koshkina, O., Chan, C., & Sobel, M. (2024). Diagnosis and management of polycystic ovarian syndrome. Canadian Medical Association Journal, 196(3), E85–E94. https://doi.org/10.1503/cmaj.231251

17. Best Practice Advocacy Centre New Zealand. (2008). Understanding polycystic ovary syndrome. Best Practice Journal. https://bpac.org.nz/bpj/2008/april/polycystic.aspx

18. Saadati, N., Haidari, F., Barati, M., Nikbakht, R., Mirmomeni, G., & Rahim, F. (2021). The effect of low glycemic index diet on the reproductive and clinical profile in women with polycystic ovarian syndrome: A systematic review and meta-analysis. Heliyon, 7(11), e08338. https://doi.org/10.1016/j.heliyon.2021.e08338

19. Sabag, A., Patten, R. K., Moreno-Asso, A., Colombo, G. E., Bouzo, X. D., Moran, L. J., Harrison, C., Kazemi, M., Mousa, A., Tay, C. T., Hirschberg, A. L., Redman, L. M., & Teede, H. J. (2024). Exercise in the management of polycystic ovary syndrome: A position statement from exercise and sport science Australia. Journal of Science and Medicine in Sport, 27(10). https://doi.org/10.1016/j.jsams.2024.05.015

20. Fernandez, R., Moore, V., Van Ryswyk, E., Varcoe, T., Rodgers, R., March, W., Moran, L., Avery, J., McEvoy, D., & Davies, M. (2018). Sleep disturbances in women with polycystic ovary syndrome: Prevalence, pathophysiology, impact and management strategies. Nature and Science of Sleep, Volume 10(2018), 45–64. https://doi.org/10.2147/nss.s127475

21. Basu, B., Chowdhury, O., & Saha, S. (2018). Possible link between stress-related factors and altered body composition in women with polycystic ovarian syndrome. Journal of Human Reproductive Sciences, 11(1), 10. https://doi.org/10.4103/jhrs.jhrs_78_17

22. Zhang, S. W., Zhou, J., Gober, HJ., Leung, W. T., & Wang, L. (2021). Effect and mechanism of berberine against polycystic ovary syndrome. Biomedicine & Pharmacotherapy, 138, 111468. https://doi.org/10.1016/j.biopha.2021.111468

23. Mishra, N., Verma, R., & Jadaun, P. (2022). Study on the effect of berberine, myoinositol, and metformin in women with polycystic ovary syndrome: A prospective randomised study. Cureus, 14(1), e21781. https://doi.org/10.7759/cureus.21781

24. Maleki, V., Faghfouri, A. H., Tabrizi, F. P. F., Moludi, J., Saleh-Ghadimi, S., Jafari-Vayghan, H., & Qaisar, S. A. (2021). Mechanistic and therapeutic insight into the effects of cinnamon in polycystic ovary syndrome: A systematic review. Journal of Ovarian Research, 14(1). https://doi.org/10.1186/s13048-021-00870-5

25. Borzoei, A., Rafraf, M., & Asghari-Jafarabadi, M. (2018). Cinnamon improves metabolic factors without detectable effects on adiponectin in women with polycystic ovary syndrome. Asia Pacific Journal of Clinical Nutrition, 27(3), 556–563. https://doi.org/10.6133/apjcn.062017.13

26. Faisal, Z., Irfan, R., Akram, N., Hafiz, Mohib Ali Aabdi, Muhammad Junaid Anwar, Sharjeel Khawar, Saif, A., Yasir Abbas Shah, Muhammad Afzaal, & Derese Tamiru Desta. (2024). The multifaceted potential of fenugreek seeds: From health benefits to food and nanotechnology applications. Food Science & Nutrition, 12(4), 2294-2310. https://doi.org/10.1002/fsn3.3959

27. Jangam, A., Kotipalli, R. S. S., Patnaik, S. S., Kasireddy, B., Gaja, S. K., Sreedhar, B., Jerald, M. K., Addlagatta, A., & Muralidharan, K. (2024). Gymnema sylvestre extract improves PCOS by altering the YAP1 protein in the mouse ovary via mitochondrial changes. Phytomedicine Plus, 4(1), 100515. https://doi.org/10.1016/j.phyplu.2023.100515

28. Ramzan, F., Jayaprakash, R., Pook, C., Foster, M., Miles-Chan, J. L., & Mithen, R. (2022). Acute effects of Kawakawa (Piper excelsum) intake on postprandial glycemic and insulinaemic response in a healthy population. Nutrients, 14(8), 1638. https://doi.org/10.3390/nu14081638

29. Koia, J. H., & Shepherd, P. (2020). The potential of anti-diabetic rākau rongoā (Māori herbal medicine) to treat type 2 diabetes mellitus (T2DM) mate huka: A review. Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.00935

30. Shamsi, M., Nejati, V., Najafi, G., & Khajeh Pour, S. (2020). Protective effects of licorice extract on ovarian morphology, oocyte maturation, and embryo development in PCOS-induced mice: An experimental study. International Journal of Reproductive BioMedicine (IJRM), 18(10). https://doi.org/10.18502/ijrm.v13i10.7771

31. Hechtman, L. (2019). Clinical naturopathic medicine (2nd ed.). Elsevier.

32. Grant, P. (2010). Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. Phytotherapy Research: PTR, 24(2), 186–188. https://doi.org/10.1002/ptr.2900

33. Akdoğan, M., Tamer, M. N., Cüre, E., Cüre, M. C., Köroğlu, B. K., & Delibaş, N. (2007). Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism. Phytotherapy Research: PTR, 21(5), 444–447. https://doi.org/10.1002/ptr.2074

34. Novakovic, S., Jakovljevic, V., Jovic, N., Andric, K., Milinkovic, M., Anicic, T., Pindovic, B., Kareva, E. N., Fisenko, V. P., Dimitrijevic, A., & Joksimovic Jovic, J. (2024). Exploring the antioxidative effects of Ginger and Cinnamon: A comprehensive review of evidence and molecular mechanisms involved in polycystic ovary syndrome (PCOS) and other oxidative stress-related disorders. Antioxidants, 13(4), 392. https://doi.org/10.3390/antiox13040392

35. Heidari, Z., Moradi, L., Farhangiyan, Z., Zakerkish, M., & Mansoori, A. (2026). The effects of ginger (Zingiber officinale) supplementation on the hormonal profile, hirsutism, amenorrhea, dysmenorrhea, and hair loss in women with polycystic ovary syndrome: A randomized double-blind, placebo-controlled trial. Journal of Functional Foods, 141, 107316. https://doi.org/10.1016/j.jff.2026.107316

36. Maleki, V., Taheri, E., Varshosaz, P., Tabrizi, F. P. F., Moludi, J., Jafari-Vayghan, H., Shadnoush, M., Jabbari, S. H. Y., Seifoleslami, M., & Alizadeh, M. (2021). A comprehensive insight into effects of green tea extract in polycystic ovary syndrome: A systematic review. Reproductive Biology and Endocrinology, 19(1). https://doi.org/10.1186/s12958-021-00831-z

37. Balasubramanian, R., Maideen, N. M. P., Muthusamy, S., & Gobinath, M. (2023). A review of clinical and preclinical studies on the therapeutic potential of black seeds (Nigella sativa) in the management of polycystic ovarian syndrome (PCOS). Journal of Pharmacopuncture, 26(1), 1–9. https://doi.org/10.3831/kpi.2023.26.1.1

38. Akter, T., Zahan, M. S., Nawal, N., Rahman, M. H., Tanjum, T. N., Arafat, K. I., Moni, A., Islam, M. N., & Uddin, M. J. (2023). Potentials of curcumin against polycystic ovary syndrome: Pharmacological insights and therapeutic promises. Heliyon, 9(6), e16957. https://doi.org/10.1016/j.heliyon.2023.e16957

39. Zoleykha Feyzollahi, Homa Mohseni Kouchesfehani, Jalali, H., Delaram Eslimi-Esfahani, & Hosseini, A. S. (2021). Effect of Vitex agnus-castus ethanolic extract on hypothalamic KISS-1 gene expression in a rat model of polycystic ovary syndrome. Avicenna Journal of Phytomedicine, 11(3), 292. https://pmc.ncbi.nlm.nih.gov/articles/PMC8140208/

40. Habryka, J., Ławniczek, M., & Krupa-Nurcek, S. (2026). Effect of myo-inositol supplementation in polycystic ovary syndrome—Scoping review. Nutrients, 18(13), 2093. https://doi.org/10.3390/nu18132093

41. Fitz, V., Graca, S., Shruthi Mahalingaiah, Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., Yang, G., Vaishnavi Vaddiparthi, Witchel, S. F., Pena, A., Poli Mara Spritzer, Li, R., Tay, C., Mousa, A., Teede, H., & Ee, C. (2024). Inositol for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 update of the International Evidence-Based PCOS Guidelines. The Journal of Clinical Endocrinology & Metabolism, 109(6), 1630-1655. https://doi.org/10.1210/clinem/dgad762

42. Viña, I., Viña, J. R., Carranza, M., & Mariscal, G. (2025). Efficacy of N-acetylcysteine in polycystic ovary syndrome: Systematic review and meta-analysis. Nutrients, 17(2), 284–284. https://doi.org/10.3390/nu17020284

43. Yuan, J., Wen, X., & Jia, M. (2021). Efficacy of omega-3 polyunsaturated fatty acids on hormones, oxidative stress, and inflammatory parameters among polycystic ovary syndrome: a systematic review and meta-analysis. Annals of Palliative Medicine, 10(8), 8991–9001. https://doi.org/10.21037/apm-21-2018

44. Jain, A., Neravi, A., Sathyasheelappa, S. K. K., & Oli, A. K. (2025). Nutritional management of polycystic ovary syndrome (PCOS)- A review. Biomedical and Pharmacology Journal, 18(1), 527–534. https://doi.org/10.13005/bpj/3105

45. Hamilton, K. P., Zelig, R., Parker, A. R., & Haggag, A. (2019). Insulin resistance and serum magnesium concentrations among women with polycystic ovary syndrome. Current Developments in Nutrition, 3(11). https://doi.org/10.1093/cdn/nzz108

Back to blog